MCO
59
-5
RL
60
-2
MAS
71
-7
SYY
49
-3
VTR
44
6
ETR
46
-3
HOG
52
-2
GLW
44
-4
VFC
38
-5
KMB
44
-4
HAS
58
-5
IP
68
-2
MSI
55
-2
DUK
47
-2
DVA
55
-2
MSFT
62
9
GILD
50
-6
HBAN
62
-6
NWS
78
-2
NUE
62
-2
MCO
59
-5
RL
60
-2
MAS
71
-7
SYY
49
-3
VTR
44
6
ETR
46
-3
HOG
52
-2
GLW
44
-4
VFC
38
-5
KMB
44
-4
HAS
58
-5
IP
68
-2
MSI
55
-2
DUK
47
-2
DVA
55
-2
MSFT
62
9
GILD
50
-6
HBAN
62
-6
NWS
78
-2
NUE
62
-2
Financhill
Back

Viridian Therapeutics 10K Form

Buy
56

VRDN
Viridian Therapeutics

Last Price:
$17.15
Seasonality Move:
-12.23%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive VRDN News And Ratings

See the #1 stock for the next 7 days that we like better than VRDN

VRDN Financial Statistics

Sales & Book Value

Annual Sales: $302K
Cash Flow: $-92.7M
Price / Cash Flow: 0
Annual Sales: $5.09
Price / Book: 3.35

Profitability

EPS (TTM): -3.85000
Net Income (TTM): $-308.3M
Gross Margin: $789K
Return on Equity: -49.8%
Return on Assets: -45.46%

Viridian Therapeutics Earnings Forecast

Key Viridian Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 5 years for VRDN is 23.64%.
  • The Selling, General & Administrative Expenses for VRDN have been equal to 20,226.16% of Gross Profit Margin.
  • The Research & Development expenses have been 78,892.05% of Revenue.
  • The Net Earning history of VRDN is -89,387.09% of Total Revenues.
  • Per Share Earnings over the last 13 years have been positive in 8 years.

Viridian Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: VRDN
Website: viridiantherapeutics.com

Debt

Debt-to-Equity Ratio: 0.03
Current Ratio: 19.49
Quick Ratio: 18.88

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

VRDN Technical Analysis vs Fundamental Analysis

Buy
56
Viridian Therapeutics (VRDN) is a Buy

Is Viridian Therapeutics a Buy or a Sell?